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ABSTRACT 
Tyrosine kinase inhibitor (TKI) therapy has revolutionised 
chronic myeloid leukaemia (CML) management, it is 
however associated with significant side effects and economic 
burden. Recent studies have demonstrated that treatment free 
remission is possible in certain patients. 
The aim of this study was to characterise a real-world 
population in terms of response to therapy, treatment 
intolerance and potential eligibility for stopping treatment.
Included were 105 CML patients diagnosed in Northern Ireland 
from March 2009-February 2018. Response to treatment was 
defined as per the 2009 and 2013 European Leukaemia Net 
guidelines. Potential for treatment cessation was assessed as 
per the 2017 UK Interim Expert Opinion on Discontinuing 
Tyrosine Kinase Inhibitor Treatment in Clinical Practice for 
Treatment-Free Remission in Chronic Myeloid Leukaemia.  
Our cytogenetic data cohort had a 12-month complete 
cytogenetic response rate of 66% and the molecular data 
cohort had a 12-month major molecular response rate of 38%. 
Of those commenced on 2nd line TKI therapy 81% achieved 
an optimal response at 12 months. Twenty-two patients 
developed intolerance and required a change in TKI therapy. 
The commonest side effects were gastro-intestinal upset 
(18%), transaminitis (16%) and fluid retention (16%). In our 
cohort, 20% were considered eligible to stop TKI therapy. The 
commonest reason for ineligibility was insufficient duration 
of therapy (25%).
We observed that 1st and 2nd line TKI therapy are effective but 
problems with failure and intolerance persist. Additionally, 
this study identifies a cohort of patients who may attempt TKI 
cessation using the UK Interim Expert Opinion report on TKI 
therapy discontinuation.
BACKGROUND
Chronic myeloid leukaemia (CML) is a myeloproliferative 
neoplasm with a reported incidence of 1-2 cases per 100,000 
adults 1. CML typically has three stages; chronic phase (CP), 
accelerated phase (AP) and blast phase (BP). As the disease 
progresses, cytogenetic abnormalities accrue, accompanied 
by symptomatic deterioration. The majority of patients are 
diagnosed during CP and most evolve into AP before BP. 
However, 20% of patients transit into an acute blastic process 
without AP warning signals 2.
Central to the pathogenesis of CML is the formation of 
the constitutively active tyrosine kinase, BCR-ABL1. This 
oncoprotein plays a key role in leukemogenesis by stimulating 
growth and replication by the manipulation of downstream 
signalling pathways and by generating a cytokine-independent 
cell cycle with aberrant apoptotic signals 3. 
Identification of this critical pathway led to the development 
of targeted drug therapy, tyrosine kinase inhibitors (TKIs), 
which interfere with the interaction between BCR-ABL1 and 
adenosine triphosphate, thereby preventing proliferation of 
the malignant clone.
The IRIS trial was a seminal study confirming the significance 
of TKIs and led to the study drug, imatinib, being approved 
for first line treatment 4. TKIs have improved the 10-year 
overall survival from approximately 20% to 80–90% 5. 
A recent study by Bower et al. demonstrated that the life 
expectancy of CML patients is approaching that of the general 
population 6.
Despite this, long term TKI therapy is associated with a heavy 
economic burden which will increase as CML becomes more 
prevalent due to improved survival 7.  Furthermore, patients 
are frequently affected by significant and occasionally lethal 
side effects. Several studies have indicated that approximately 
half of patients who achieve a deep and sustained molecular 
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response can safely and successfully stop TKI therapy and 
obtain treatment free remission (TFR) 8. 
In patients with a molecular recurrence necessitating 
resumption of TKI therapy, the overwhelming majority 
retained their sensitivity to TKI therapy. In all major published 
trials to date, only one case has been identified where a patient 
progressed to BP despite therapy recommencement 9.
Although numerous trials have confirmed the safety and 
efficacy of TKIs, assessment of their real-world effectiveness 
and tolerance in a general CML population is scarce. 
Furthermore, identifying patients who may attempt to gain 
TFR is a relatively novel strategy.
The aim of this study was to provide a detailed description 
of the presentation and management of a real-world sample 
of CML patients. We sought to assess the effectiveness and 
tolerance of TKI therapy and evaluate what proportion of 
participants were deemed eligible to stop TKI therapy in an 
attempt to obtain TFR.
METHODS
This study included 105 CML patients diagnosed from 
March 2009 to February 2018 and managed by the Belfast 
City Hospital Haematology Department. This cohort was 
identified by interrogation of Consultant patient records. 
Patients not managed by this tertiary centre were not included. 
Data was collected using patient medical notes and electronic 
laboratory records. 
Table 1: 
Baseline Characteristics of the Study Population 
Characteristic Study Population 
Number of Patients 105
Median Age (range)- years 61.5 (4-94)
Male sex- no. (%) 62 (59)
Palpable splenomegaly no. (%) 50 (48)
Median haemoglobin for males 
(range)- g/l 118.5 (67-155)
Median haemoglobin for females 
(range)- g/l 110 (64-148)
Median platelet count (range)- x109/l 96.8 (13.4-563)
Median white cell count (range)- 
x109/l 340 (84-2507)
EUTOS risk group-no. (%)  
Low 89 (85)
High 5 (5)
Unknown 11 (10)
Phase- no. (%)  
Chronic 99 (94)
Unknown 6 (6)
Cytogenetic analysis and BCR-ABL1 transcript analysis 
were performed at a single centre (Haematology Laboratory, 
Belfast City Hospital). Transcript analysis was conducted 
using quantitative polymerase chain reaction technology. 
Results for response to treatment were expressed as per the 
2009 and 2013 European Leukaemia Net (ELN) guidelines 
and applied retrospectively, depending on the date of 
diagnosis 10,11. Potential for treatment discontinuation was 
assessed as per the eligibility criteria expressed by the 2017 
UK Interim Expert Opinion on Discontinuing Tyrosine Kinase 
Inhibitor Treatment in Clinical Practice for Treatment-Free 
Remission in Chronic Myeloid Leukaemia 12. 
Data were analysed using descriptive statistics and IBM 
SPSS® software was used. 
RESULTS
Presenting Features
This study included 105 patients (62 males, 43 females) with a 
median age at diagnosis of 61.5 years. Baseline characteristics 
are shown in Table 1. The most common presenting symptoms 
were fatigue (32%), unintentional weight loss (24%) and 
night sweats (17%). 30% of patients were diagnosed as a 
result of an incidental finding. At diagnosis the majority of 
males and females were anaemic, 77% and 63% respectively. 
Moreover, 38% of patients were thrombocythaemic and 7% 
were thrombocytopenic. 
Treatment and Response to Therapy 
The majority of patients (74%) did not receive cyto-
reduction prior to TKI initiation. However, 23% did receive 
hydroxycarbamide and 3% underwent leucopheresis. The 
most commonly prescribed 1st line TKI was imatinib (81%) 
with the remainder receiving 2nd generation TKI therapy, 
namely nilotinib (12%) and dasatinib (7%).
The response to 1st line TKI therapy was assessed, using 
cytogenetic data, in 57 patients in accordance with the 2009 
ELN guidelines 10. Cytogenetic data was not always available 
because of a lack of bone marrow biopsy data, probably 
arising from clinician reluctance to subject patients to an 
invasive procedure, especially if symptoms had resolved 
along with a downward trending BCR-ABL1 transcript level. 
See Table 2 for availability at the various timepoints.  In 
those with cytogenetic data available 79%, 72% and 66% 
achieved an optimal response to therapy at 3, 6 and 12 months 
respectively (Table 2). Whereas, 14%, 12%, and 6% of 
patients were determined to have a failure response to therapy. 
The response to 1st line TKI therapy was assessed, using 
molecular data, in 47 patients in accordance with the 2013 
ELN guidelines 11. Due to a lack of compulsory monitoring 
molecular data was not always available (Table 3).  In those 
with molecular data available, 50%, 43% and 38% achieved 
an optimal response to therapy at 3, 6 and 12 months 
respectively (Table 3). However, 9%, 22% and 15% of 
patients were determined to have a failure response to therapy. 
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Monitoring was much more stringent in this cohort due to the 
less invasive sampling required for transcript analysis.
A total of 28 patients required a change in TKI therapy due 
to an inadequate cytogenetic and or molecular response. 
Subsequently, they were commenced on 2nd line therapy in an 
attempt to obtain disease control and to prevent progression. 
These patients were assessed for an optimal response to 2nd 
line therapy as defined by the 2013 ELN guidelines 11. In those 
with molecular data available, 78%, 86% and 81% achieved an 
optimal response at 3, 6 and 12 months respectively (Table 4). 
Treatment Intolerance
Initial TKI therapy was changed in 47% of patients due to 
inadequate response (26%), treatment intolerance (18%) and 
study completion (3%). Throughout their entire treatment 
regime 22 patients were identified who due to intolerance 
required a change in therapy. Among these 22 patients 
there were 38 instances of a change in TKI therapy, thereby 
highlighting that several patients experienced intolerable 
side effects to more than one agent. The most common side 
effects resulting in a change in therapy were gastrointestinal 
upset (18%), transaminitis (16%) and fluid retention (16%) 
(Figure 1). 
Eligibility for TKI Discontinuation
The cohort of patients was assessed for eligibility to stop 
TKI therapy in accordance with a recently published UK 
Interim Expert Opinion on TKI discontinuation 12. This 
report advises that TKI discontinuation may be attempted 
in adult patients with no prior history of AP or BP disease. 
Moreover, the patient must have been on TKI therapy for at 
least 3 years and have had a sustained response i.e. (BCR-
ABL1 ≤0.01%) throughout the last 2 years prior to attempted 
discontinuation12. 
Fig 1; Side Effects Associated with Tyrosine Kinase Inhibitor 
Therapy Resulting In a Change in Therapy 
Table 2: 
Response to 1st Line TKI Therapy as Defined by the 2009 ELN Guidelines 
Response to Therapy 
 Optimal Suboptimal Failure Unknown Deceased No Bone Marrow 
Biopsy
2nd Line Therapy 
Commenced
3 Months 11 1 2 2 1 40 0
6 Months 18 3 3 1 1 30 1
12 Months 23 7 2 2 1 19 3
Table 3: 
Response to 1st Line TKI Therapy as Defined by the 2013 ELN Guidelines
Response to Therapy 
 Optimal Warning Failure Unknown Deceased Awaited 2nd Line Therapy Commenced
3 Months 17 14 3 9 1 3 0
6 Months 16 12 8 6 1 3 1
12 Months 15 11 6 4 1 3 7
Table 4: 
Response to 2nd Line TKI Therapy as Defined by the 2013 ELN Guidelines 
Response to Therapy 
 Optimal Warning or Failure Unknown Deceased Awaited 3rd Line Therapy Commenced
3 Months 14 4 9 0 1 0
6 Months 18 3 5 1 1 0
12 Months 14 6 3 2 2 1
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In this cohort 20% were considered eligible to stop TKI 
therapy in an attempt to obtain TFR. Reasons for ineligibility 
included insufficient duration of therapy (25%), history of 
inadequate response to therapy (16%) and a BCR-ABL1 
transcript level ≥ 0.01 within the past 2 years (16%) (Figure 2).
Fig 2. Reasons for Failure to Meet Eligibility Criteria as Defined 
by the 2017 UK Interim Expert Opinion on Discontinuing 
Tyrosine Kinase Inhibitor Treatment in Clinical Practice for 
Treatment Free Remission in Chronic Myeloid Leukaemia
Follow Up
This population of patients were followed up until March 
2018. During follow up 18 out of 105 patients died, however, 
only 1 death was attributable to a CML blast crisis. One 
patient died from complications of a bone marrow transplant 
and a further patient died from acute liver failure attributed 
to imatinib therapy. Other common causes of death included 
sepsis and solid malignancy. 
Annual BCR-ABL1 transcript levels were assessed to 
determine what proportion of patients achieved a major 
molecular response (MMR). MMR is defined as a 3-log 
reduction in transcript levels from the standardised baseline 
or a transcript level of <0.1 in the International Scale 13.
Data suggests that the proportion of patients achieving and 
maintaining a MMR increases as time passes. Molecular 
follow up data at 2 years revealed that 63% achieved a MMR, 
at 5 years 83% achieved a MMR and at 8 years 100% of 
patients, still alive, had achieved a MMR. At the time of data 
analysis 8 patients had reached 8 years of follow up; all of 
whom had achieved a MMR. 
DISCUSSION
Real-world data has important implications that inform 
clinical practice. The aim of this study was to provide such 
data on the presentation, management and outcomes of a 
CML population. We sought to highlight issues with treatment 
failure and intolerance and to identify a cohort of patients, 
using recently published guidance, who could stop therapy 
in an attempt to obtain TFR. 
Advances in the understanding of the pathophysiology of 
CML have led to the development of targeted therapy which 
has changed management. However, a substantial number of 
patients suffer significant intolerance to TKI therapy. In this 
study 21% of patients experienced intolerance to one or more 
TKIs, necessitating a change in therapy. Side effects such as 
gastro-intestinal upset and transaminitis were common across 
the entire class of drugs. Certain characteristic side effects 
were coupled with particular TKIs as demonstrated by the 
relationship between dasatinib therapy and pleural effusions. 
It is essential that the clinician adopts a proactive stratagem 
to manage side effects. The association of side effect burden 
and poor medication adherence with a suboptimal disease 
response demands that side effects are managed aggressively. 
With unmanageable side effects it is appropriate to switch 
TKI therapy and with 3rd generation TKIs filtering into clinical 
practice, this will promote the therapeutic armoury available 
14. Our results mirror other real-world studies which have 
demonstrated that 41-44% of patients change TKI therapy 
due to treatment intolerance or failure 15,16. 
Furthermore, TKI therapy is associated with substantial 
financial implications. As the life expectancy of CML patients 
now approaches that of the general population, the provision 
of life long therapy is expensive 6. Consequently, TFR is an 
attractive therapeutic target for the health service.  Analysis 
by Padula et al, suggests that the annual cost of imatinib 
therapy per patient in the United States was almost $80,000 
per year and introduction of generic imatinib resulted in only 
a modest decrease in cost 17. Therefore, safely stopping TKI 
therapy represents a substantial cost saving.  However, it must 
be remembered that achievement of TFR will have its own 
unique costs. Patients will require closer monitoring and there 
is an argument for indefinite BCR-ABL1 transcript analysis 
to safe guard against a delayed diagnosis of disease relapse 
and to help inform clinical practice regarding the long-term 
durability of TFR. Regardless, the standard cost of performing 
a transcript assay in our unit is £200, therefore, compared 
to one year of TKI therapy, regular molecular monitoring 
remains highly cost effective. 
Our cytogenetic data cohort had a 12-month complete 
cytogenetic response (CCyR) rate of 66% and the molecular 
data cohort had a 12-month MMR rate of 38%; comparable 
to other population-based registries 15,18,19. The EUTOS 
registry, one of the largest CML population-based registries, 
had a 12-month CCyR rate of 57% and a MMR rate of 41% 
19. Interestingly, our results compare favourably to Lucas 
et al., who using a surrogate end point CCyR equivalence 
(CCRe) which combined molecular expression data and 
cytogenetic data, revealed a 12-month CCyR equivalence rate 
of approximately 41% within a real-world UK population of 
CML patients treated with imatinib 20. However, a proportion 
of patients in our study were treated with first line 2nd 
generation TKIs which have been demonstrated to induce 
earlier and higher rates of CCyR and MMR compared to 
imatinib 21,22. This may partially account for the difference in 
12-month response rates.   
Stopping TKI therapy provides a novel opportunity to 
obtain TFR for approximately 40% - 60% of patients 8. 
The STIM trial was one of the first studies to confirm the 
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possibility of achieving TFR. This study highlighted that 
most patients who relapsed did so within the first 6 months 
of treatment discontinuation and that all patients who 
relapsed remained sensitive to imatinib re-introduction 23. 
The safety of imatinib discontinuation was re-affirmed by the 
TWISTER trial 24. Moreover, interim analysis of the STOP 
2G-TKI study revealed that discontinuation of 2nd generation 
TKIs yields promising TFR rates in addition to allowing 
effective re-introduction of TKIs without safety concerns 
25. The safety and stability of response in those who have 
successfully achieved TFR has been recently reaffirmed by 
the Australasian Leukaemia & Lymphoma Group (ALLG). 
The ALLG have previously demonstrated the persistence of 
BCR-ABL1-positive cells, even in patients with a sustained 
TFR 26. They have now revealed that despite an absence of 
ongoing TKI therapy, there is an ongoing fall in minimal 
residual disease 27. 
The exact pre-conditions for identifying patients suitable for 
TKI therapy cessation without fear of molecular relapse are 
currently unknown. However, several studies have begun 
to address this. The STOP 2G-TKI study identified that a 
history of TKI treatment resistance was predictive of potential 
molecular relapse, whereas the EURO-SKI trial highlighted 
that a longer duration of imatinib therapy was significantly 
associated with a higher probability of molecular relapse free 
survival 25,28.  
The clinician must recognise the potential problems 
associated with TKI discontinuation. In addition to disease 
relapse, the psychological impact of stopping TKI therapy 
must be considered. An Italian survey revealed that almost 
50% of patients had concerns over stopping TKI therapy due 
to potential disease relapse 29. Moreover, a relatively new 
entity to emerge from discontinuation is the TKI withdrawal 
syndrome, affecting up to 60% of patients and typically 
manifesting as musculo-skeletal pain. It is often self-limiting 
but may persist for several months and require treatment with 
simple analgesia 30. 
Little data exists on application of eligibility criteria in a CML 
population outside clinical trial milieux. Using the 2017 UK 
Interim Expert Report we identified that 20% of patients 
could stop TKI therapy, whereas, utilising the EURO-SKI 
criteria Geelen et al, only 11% of patients met the eligibility 
criteria 15. 
There are limitations to our study. This was a population-
based study and those involved were not monitored as 
strictly as during a clinical trial. The International Scale for 
reporting BCR-ABL1 results was only recently available to 
our laboratory, therefore the majority of results were reported 
using the local assay.
CONCLUSION
In conclusion, our real-world observations show that 1st 
and 2nd line TKI therapy is effective, however problems 
with treatment intolerance and failure remain. Additionally, 
this study identifies a cohort of patients, using the recently 
published 2017 UK Interim Expert Opinion on Discontinuing 
TKI Treatment guidelines, who may attempt TKI therapy 
cessation. Our findings have revealed that criteria for an 
attempt to stop TKI therapy are met by one fifth of patients.
REFERENCES
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA: Cancer J 
Clin. 2017;67(1):7-30.
2. Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2016 update on 
diagnosis, therapy, and monitoring. Am J Hematol. 2016;91(2):252-65.
3. Ren R. Mechanisms of BCR–ABL in the pathogenesis of chronic 
myelogenous leukaemia. Nat Rev Cancer. 2005;5(3):172-6.
4. O’Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes 
F, et al. Imatinib compared with interferon and low-dose cytarabine for 
newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J 
Med. 2003;348(11):994-1004.
5. Deininger M, O’Brien SG, Guilhot F, Goldman JM, Hochhaus A, 
Hughes TP, et al. International Randomized Study of Interferon Vs 
STI571 (IRIS) 8-Year Follow up: sustained survival and low risk for 
progression or events in patients with newly diagnosed chronic myeloid 
leukemia in chronic phase (CML-CP) treated with Imatinib. Blood. 
2009; 114(22): 1126
6. Bower H, Bjorkholm M, Dickman PW, Hoglund M, Lambert PC, 
Anderson TM. Life expectancy of patients with chronic myeloid 
leukemia approaches the life expectancy of the general population. J 
Clin Oncol. 2016; 34(24):2851-7.
7. Ross DM, Hughes TP. How I determine if and when to recommend 
stopping tyrosine kinase inhibitor treatment for chronic myeloid 
leukaemia. Br J Haematol. 2014;166(1):3-11.
8. Kimura S. Current status of ABL tyrosine kinase inhibitors stop studies 
for chronic myeloid leukemia. Stem Cell Investig 2016 Aug 9;3:36.
9. Rousselot P, Charbonnier A, Cony-Makhoul P, Agape P, Nicolini 
FE, Varet B, et al. Loss of major molecular response as a trigger for 
restarting tyrosine kinase inhibitor therapy in patients with chronic-phase 
chronic myelogenous leukemia who have stopped imatinib after durable 
undetectable disease. J Clin Oncol. 2014;32(5):424-30.
10. Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley 
J, et al. Chronic myeloid leukemia: an update of concepts and 
management recommendations of European LeukemiaNet. J Clin 
Oncol. 2009;27(35):6041-51.
11. Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley 
JF, et al. European LeukemiaNet recommendations for the management 
of chronic myeloid leukemia: 2013. Blood. 2013;122(6):872-84.
12. Clark R, Copland M, Goringe A, Huntly B, Milojkovic D, Mead A, et al. 
UK Interim Expert Opinion on discontinuing tyrosine kinase inhibitor 
treatment in clinical practice for treatment-free remission in chronic 
myeloid Leukaemia.  Geneva: Novartis Medical Affairs and Medical 
Information; 2017.  Available from: http://nssg.oxford-haematology.
org.uk/myeloid/guidelines/TAS17-E010-final-uk-interim-
expert-opinion-tfr.pdf. [Accessed Jan 2019.]
13. Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML, 
et al. Frequency of major molecular responses to imatinib or interferon 
alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N 
Engl J Med. 2003;349(15):1423-32.  
14. Deangelo D. Managing chronic myeloid leukemia patients intolerant 
to tyrosine kinase inhibitor therapy. Blood Cancer J. 2012;2(10):e95.
15. Geelen IG, Thielen N, Janssen JJ, Hoogendoorn M, Roosma TJA, 
Willemsen SP, et al. Treatment outcome in a population-based, ‘real-
world’ cohort of patients with chronic myeloid leukemia. Haematologica. 
2017;102(11):1842-9.
110 The Ulster Medical Journal
UMJ is an open access publication of the Ulster Medical Society (http://www.ums.ac.uk).
The Ulster Medical Society grants to all users on the basis of a Creative Commons Attribution-NonCommercial-ShareAlike 
4.0 International Licence the right to alter or build upon the work non-commercially, as long as the author is credited 
and the new creation is licensed under identical terms.
16. Castagnetti F, Di Raimondo F, De Vivo A, Spitaleri A, Gugliotta G, 
Fabbiano F, et al. A population-based study of chronic myeloid leukemia 
patients treated with imatinib in first line. Am J Hematol. 2017;92(1):82-7.
17. Padula WV, Larson RA, Dusetzina SB, Apperley JF, Hehlmann R, 
Baccarani M, et al. Cost-effectiveness of tyrosine kinase inhibitor 
treatment strategies for chronic myeloid leukemia in chronic phase 
after generic entry of imatinib in the United States. J Natl Cancer Inst. 
2016;108(7): djw003.
18. Hoglund M, Sandin F, Hellstrom K, Bjoreman M, Bjorkholm M, Brune 
M, et al. Tyrosine kinase inhibitor usage, treatment outcome, and 
prognostic scores in CML: report from the population-based Swedish 
CML registry. Blood. 2013;122(7):1284-92.
19. Hoffmann V, Baccarani M, Hasford J, Castagnetti F, Di Raimondo F, 
Casado L, et al. Treatment and outcome of 2904 CML patients from 
the EUTOS population-based registry. Leukemia. 2017;31(3):593-601.
20. Lucas CM, Wang L, Austin GM, Knight K, Watmough SJ, Shwe KH, 
et al. A population study of imatinib in chronic myeloid leukaemia 
demonstrates lower efficacy than in clinical trials. Leukemia. 
2008;22(10):1963-6.
21. Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boque C, 
et al. Final 5-year study results of DASISION: The Dasatinib Versus 
Imatinib Study in Treatment-Naive Chronic Myeloid Leukemia Patients 
Trial. J Clin Oncol. 2016;34(20):2333-40.
22. Hochhaus A, Saglio G, Hughes TP, Larson RA, Kim DW, Issaragrisil 
S, et al. Long-term benefits and risks of frontline nilotinib vs imatinib 
for chronic myeloid leukemia in chronic phase: 5-year update of the 
randomized ENESTnd trial. Leukemia. 2016;30(5):1044-54.
23. Mahon FX, Réa D, Guilhot J, Guilhot F, Huguet F, Nicolini F, et al. 
Discontinuation of imatinib in patients with chronic myeloid leukaemia 
who have maintained complete molecular remission for at least 2 years: 
the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 
2010;11(11):1029-35.
24. Ross DM, Branford S, Seymour JF, Schwarer AP, Arthur C, Yeung DT, 
et al. Safety and efficacy of imatinib cessation for CML patients with 
stable undetectable minimal residual disease: results from the TWISTER 
study. Blood. 2013;122(4):515-22.
25. Rea D, Nicolini FE, Tulliez M, Guilhot F, Guilhot J, Guerci-Bresler A, et 
al. Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: 
interim analysis of the STOP 2G-TKI study. Blood. 2017;129(7):846-54.
26. Ross DM, Branford S, Seymour JF, Schwarer AP, Arthur C, Bartley PA, 
et al. Patients with chronic myeloid leukemia who maintain a complete 
molecular response after stopping imatinib treatment have evidence of 
persistent leukemia by DNA PCR. Leukemia. 2010;24(10):1719-24.
27. Ross DM, Pagani IS, Shanmuganathan N, Kok CH, Seymour JF, Mills 
AK, et al. Long-term treatment-free remission of chronic myeloid 
leukemia with falling levels of residual leukemic cells. Leukemia. 
2018;32:2572–9.
28. Mahon F, Richter J, Guilhot J, Hjorth-Hansen H, Almeida A, Janssen 
JJJ, et al. Cessation of tyrosine kinase inhibitors treatment in chronic 
myeloid leukemia patients with deep molecular response: results of the 
Euro-Ski trial. Blood 2016; 128(22):787
29. Breccia M, Efficace F, Sica S, Abruzzese E, Cedrone M, Turri D, et 
al. Adherence and future discontinuation of tyrosine kinase inhibitors 
in chronic phase chronic myeloid leukemia. A patient-based survey on 
1133 patients. Leuk Res. 2015;39(10):1055-9.
30. Richter J, Soderlund S, Lubking A, Dreimane A, Lotfi K, Markevarn B, 
et al. Musculoskeletal pain in patients with chronic myeloid leukemia 
after discontinuation of imatinib: a tyrosine kinase inhibitor withdrawal 
syndrome? J Clin Oncol. 2014;32(25):2821-3.
